Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...

Novo Nordisk's (NVO) stock was up more than 8% in trading Friday on news the company's latest weight loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Medicare plans to negotiate prices for Novo Nordisk products Ozempic (an injection to control diabetes), Wegovy (an injection more designed for weight loss), and Rybelsus (a pill for diabetes).

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and ...

No Plan to Prop up Global Health, Novo Nordisk Foundation Says, as Trump Freezes US Aid By Jennifer Rigby LONDON (Reuters) - The Novo Nordisk Foundation does not plan to step in to prop up a ...

As of 11 a.m. ET, shares of Novo Nordisk (NYSE: NVO) are down 4.2%, and Hims & Hers Health (NYSE ... plans to negotiate prices for Novo Nordisk products Ozempic (an injection to control diabetes ...